No 14 (2010)

In the literature review questions of pathogenesis of uterine myoma LMM, with accent on hormonal regulation of tumours proliferation are considered. The doubtless role of a progesterone in the pathogenesis of myomas is an adequate substantiation of application antigestagenes in disease therapy. Successful clinical application mifepristone confirms the leading part of a progesterone in the control of growth of a myoma. Now medicamentous treatment of a myoma of a uterus is not ideal, nevertheless, from all spectrum of offered approaches use antigestagenes (mifepristone), considering its high efficiency and safety, it has appeared the most comprehensible.

The present article is dedicated to the problem of magnesium deficiency (MD) that is caused by increasing frequency of MD among examined patients and its proved relationship with a wide spectrum of diseases and the pathological conditions associating with endothelial dysfunction, apoptosis defect, metabolic and hypertensive syndromes, pathology of connective tissue, and problems of immunity. MD has particular significance at pregnancy, since conception and its earliest terms, because magnesium is universal regulator of biochemical and physiological processes in an organism. It has been established that magnesium deficiency makes particular contribution in the development of pregnancy complications that defines an important role of preventive use of magnesium preparations since preconception period.

Insufficient consumption of vitamins and micronutrients leads to disorders of biochemical processes and physiological functions of organism, as well as causes serious metabolic disturbance, and abnormal formation and fetal development during pregnancy. The folic acid is major vitamin participating in synthesis of DNA, coenzymes and regulation of many processes in an organism. Sufficient intake of folic acid before pregnancy and on its early terms reduces risk of development of neural tube defects, Down's syndrome, and anomalies of cardiovascular and urinary systems, formation of palatoschisis and other defects. Recommended daily intake of folic acid for adults is 400 mcg, but during pregnancy it raises to 400-800 mcg, and during lactation - 600 mcg. As a consequence, administration of balanced diet and vitamin preparations are necessary.

The article is dedicated to the results of two studies of use of microcellulose powder (Nasaval) and microcellulose with moly extract (Nasaval Plus). The results represent a modern trend in prevention of contact of allergens and viruses with nasal mucosa by creation on its surface gelatinoid substance. Administration of drug Nasaval before expected allergic reaction allows to reduce clinical implications of allergic rhinitis, conjunctivitis and asthmatic attack without additional treatment. Use of a drug Nasaval Plus for the purpose of prophylaxis significantly prevents occurrence of droplet infections and reinfection. Use of Nasaval Plus in the treatment of active acute respiratory viral infection promotes reduction of duration and severity of disease.

The present article is concerned with inhibitor-protected antibiotic Amoxicillin/Klavulanat (Augmentin) with high efficiency in the treatment of infections of respiratory tract, soft tissues and urinary system. Currently, the most preparations of Amoxicillin/Klavulanat were developed with component ratio 4: 1, however experimental and clinical researches have shown benefits of "advanced" preparations with higher component ratio, in particular 16: 1 (Augmentin XR) and 14: 1 - a pediatric syrup Augmentin ES. It was shown that Augmentin ES is effective in the treatment of acute otitis media, particularly in otitis caused by pneumococci with the decreased sensitivity, as well as caused by β-lactamase - producing H. influenzae and M. catarrhalis. The preparation is effective in the treatment of acute bacterial sinusitis caused by the same flora, and in the treatment of other infections, for example caused by staphilococci with higher minimal inhibitory concentration in relation to Amoxicillin.

14 pregnant women ages 18 to 38 years at 22-36 weeks of gestation in good general health and without recent or concurrent febrile illness, gave written informed consent to receive immunization with influenza A/Brisbane/59/2007 (HlNl), A/Brisbane /10/2007 (HlN2), B/Florida/4/2006 vaccine Agrippal S1. There were no significant side effects after immunization in any of the women. Antibody titers were determined to A/Brisbane/59/2007 (HlNl), A/Brisbane /10/2007 (HlN2), B/Florida/4/2006 before and after a single dose of influenza vaccine. Protective titers to all three strains of vaccine were detected in 13 pregnant women.